Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells
Thompson, J.A.; Benyunes, M.C.; Bianco, J.A.; Fefer, A.
Seminars in Oncology 20(6 Suppl 9: 46-51
1993
ISSN/ISBN: 0093-7754 PMID: 8284692 Document Number: 410241
Document emailed within 1 workday
Related Documents
Marcus, S.L.; Dutcher, J.P.; Paietta, E.; Ciobanu, N.; Strauman, J.; Wiernik, P.H.; Hutner, S.H.; Frank, O.; Baker, H. 1987: Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells Cancer Research 47(15): 4208-4212Glassman, A.B. 1989: Interleukin-2 and lymphokine activated killer cells: promises and cautions Annals of Clinical and Laboratory Science 19(1): 51-55
Kanai, T.; Monden, M.; Takeda, T.; Gotoh, M.; Sakon, M.; Umeshita, K.; Hasuike, Y.; Sakita, I.; Nakano, H.; Yoshida, T. 1993: Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(11): 1457-1460
Kaufmann, Y.; Levanon, M.; Davidsohn, J.; Ramot, B. 1987: Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity Journal of Immunology 139(3): 977-982
Stewart, J.A.; Belinson, J.L.; Moore, A.L.; Dorighi, J.A.; Grant, B.W.; Haugh, L.D.; Roberts, J.D.; Albertini, R.J.; Branda, R.F. 1990: Phase i trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer Cancer Research 50(19): 6302-6310
Marincola, F.M.; Da Pozzo, L.F.; Drucker, B.J.; Holder, W.D. 1990: Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model Surgery 108(5): 919-929
Blacklock, J.B.; Grimm, E.A. 1989: Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system Immunology Series 48: 93-99
Yasumoto, K.; Mivazaki, K.; Nagashima, A.; Ishida, T.; Kuda, T.; Yano, T.; Sugimachi, K.; Nomoto, K. 1987: Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer Cancer Research 47(8): 2184-2187
Shiloni, E.; Lafreniere, R.; Mulé, J.J.; Schwarz, S.L.; Rosenberg, S.A. 1986: Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice Cancer Research 46(11): 5633-5640
Lamers, H.J.; Gratama, J.W.; van Putten, W.L.; Stoter, G.; Bolhuis, R.L. 1991: Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes Cancer Research 51(9): 2324-2328
Merluzzi, V.J.; Trail, P.A.; Last-Barney, K. 1986: Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow Journal of Immunology 137(8): 2425-2427
Sznol, M.; Clark, J.W.; Smith, J.W.; Steis, R.G.; Urba, W.J.; Rubinstein, L.V.; VanderMolen, L.A.; Janik, J.; Sharfman, W.H.; Fenton, R.G. 1992: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma Journal of the National Cancer Institute 84(12): 929-937
Law, K.Seng.; Chen, H-Chang.; Liao, S-Kuei. 2007: Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells Anticancer Research 27(2): 841-850
Weil-Hillman, G.; Voss, S.D.; Fisch, P.; Schell, K.; Hank, J.A.; Sosman, J.A.; Sugamura, K.; Sondel, P.M. 1990: Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype Cancer Research 50(9): 2683-2691
Chen, M.F.; Suzuki, H.; Yano, S. 1992: Induction of murine lymphokine-activated killer-like cells by Corynebacterium parvum (C. parvum) in vitro: lysis of tumor cells and macrophages by C. parvum-induced killer cells Anticancer Research 12(2): 451-456
Itoh, K.; Tilden, A.B.; Kumagai, K.; Balch, C.M. 1985: Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells Journal of Immunology 134(2): 802-807
Liu, G.R. 1993: Cytotoxicity of human lymphokine-activated killer cells against mitotic phase tumor cells Zhonghua Yi Xue Za Zhi 73(9): 547-548; 576
Montagna, D.; Maccario, R.; Ugazio, A.G.; Mingrat, G.; Burgio, G.R. 1988: Natural cytotoxicity in the neonate: high levels of lymphokine activated killer (LAK) activity Clinical and Experimental Immunology 71(1): 177-181
Lynch, D.H.; Miller, R.E. 1990: Induction of murine lymphokine-activated killer cells by recombinant IL-7 Journal of Immunology 145(6): 1983-1990
Hamada, F.; Fuchimoto, S.; Orita, K. 1989: Suppression of lymphokine activated killer (LAK) cells by immunosuppressive substance Research Communications in Chemical Pathology and Pharmacology 65(1): 81-95